Shares of Ophthotech Corp (NASDAQ:OPHT) have been given an average rating of “Buy” by the four research firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $3.63.

Several brokerages have recently commented on OPHT. ValuEngine lowered Ophthotech from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. TheStreet upgraded Ophthotech from an “e+” rating to a “c” rating in a research report on Thursday, November 30th. Finally, Zacks Investment Research upgraded Ophthotech from a “hold” rating to a “strong-buy” rating and set a $3.25 price objective on the stock in a research report on Monday, November 13th.

Shares of Ophthotech (OPHT) traded down $0.09 during trading on Wednesday, hitting $2.67. The stock had a trading volume of 257,943 shares, compared to its average volume of 401,895. The company has a market cap of $96.40, a price-to-earnings ratio of 1.71 and a beta of 1.43. Ophthotech has a 12-month low of $2.24 and a 12-month high of $4.81.

In related news, CEO Glenn Sblendorio sold 8,089 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total transaction of $25,803.91. Following the transaction, the chief executive officer now directly owns 44,584 shares in the company, valued at approximately $142,222.96. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider David R. Guyer sold 16,520 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $3.19, for a total value of $52,698.80. Following the transaction, the insider now owns 50,494 shares in the company, valued at $161,075.86. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 34,971 shares of company stock worth $111,481. 2.00% of the stock is owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of OPHT. Wells Fargo & Company MN grew its position in Ophthotech by 182.2% during the 4th quarter. Wells Fargo & Company MN now owns 33,160 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 21,411 shares during the last quarter. Alambic Investment Management L.P. bought a new stake in shares of Ophthotech in the 4th quarter worth approximately $211,000. Two Sigma Investments LP bought a new stake in shares of Ophthotech in the 4th quarter worth approximately $367,000. Eversept Partners LLC bought a new stake in shares of Ophthotech in the 4th quarter worth approximately $465,000. Finally, Acadian Asset Management LLC bought a new stake in shares of Ophthotech in the 4th quarter worth approximately $622,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2018/02/14/ophthotech-corp-opht-receives-average-rating-of-buy-from-brokerages.html.

Ophthotech Company Profile

Ophthotech Corporation is a biopharmaceutical company. The Company is engaged in the development of therapeutics to treat ophthalmic diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness.

Receive News & Ratings for Ophthotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ophthotech and related companies with MarketBeat.com's FREE daily email newsletter.